The sharpest verdict: brenipatide's Psych Congress 2026 announcement is a strategic declaration, not an evidence-based efficacy claim. The sole dataset — a Phase 1 multiple ascending dose study in 212 individuals (184 brenipatide, 28 placebo) — establishes only that gastrointestinal TEAEs occurred at 25% in both the brenipatide and placebo groups, a tolerability signal notable for a GLP-1/GIP class historically burdened by GI adverse events, but carrying the lowest usable evidence weight. No efficacy data in alcohol use disorder or major depressive disorder exist at any controlled evidence tier. The program advances directly from Phase 1 to two simultaneous Phase 3 trials — RENEW-ALC-1 (AUD) and RENEW-MDD-1 (MDD) — without an intervening randomized Phase 2 proof-of-concept in either neuropsychiatric indication, a structurally high-risk development path. No precedent clears the mechanistic-fit bar: no dual GLP-1/GIP receptor agonist has previously been evaluated in AUD or MDD at any pivotal level. Contextual precedents from AUD pharmacotherapy (nalmefene, naltrexone — both opioid-system modulators, mechanistically distinct) and MDD HTA decisions (esketamine — NMDA antagonist, mechanistically distinct) confirm that payers require active comparator data and consistent efficacy across trials, and that novel mechanisms alone do not secure reimbursement. [1][2] The semaglutide AUD Phase 3 RCT (GLP-1R agonist only, partial mechanistic overlap, Phase 3 RCT evidence tier) demonstrated a statistically significant treatment difference of -13.7 percentage points in heavy drinking days (p=0.0015) in an obesity-comorbid population on background CBT — the closest available clinical signal for the GLP-1 mechanism in AUD, but not a clean precedent for brenipatide's dual mechanism or its undefined trial population. [3] The sharpest risk: if RENEW-ALC-1 does not enroll obesity-comorbid patients or mandate concomitant psychosocial support — design details absent from available evidence — the trial may be structurally misaligned with the population where the GLP-1 mechanism has shown its strongest signal.
The sole dataset is a single-arm Phase 1 MAD study (184 brenipatide, 28 placebo) reporting GI TEAE parity with no efficacy endpoints; no Phase 2 randomized data exist in AUD or MDD, and Phase 3 topline results are not expected until early 2028.
| Indication | Alcohol use disorder |
| Drug | brenipatide |
| Mechanism of Action | GLP-1 and GIP receptor agonist |
| Company | Eli Lilly |
| Trial Phase | Phase 3 |
| Trial Acronym | RENEW-ALC-1 |
| NCT ID | NCT07219966 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Neutral / Mixed |
| Therapeutic Area | Neuroscience |
| Conference Name | Psych Congress 2026 |
| Patient Population (Phase 1) | 212 individuals (184 on brenipatide, 28 on placebo) |
| Primary Endpoint (RENEW-ALC-1) | Change in drinking patterns |
| Primary Endpoint (RENEW-MDD-1) | Delaying the return of major depressive symptoms |
| Half-life | Nine to 12 days |
| Topline Data Expected | Early 2028 |
| Other Indications (Phase 2) | Opioid use disorder, tobacco use disorder, bipolar disorder, schizophrenia, asthma, irritable bowel syndrome, chronic obstructive pulmonary disease (COPD) |
| Trial Acronym (MDD) | RENEW-MDD-1 |
| Trial NCT ID (MDD) | NCT07412756 |
Lilly Unveils Early Brenipatide Data for Depression, Alcohol Use Disorder
Eli Lilly presented early-stage data at Psych Congress 2026 for brenipatide, its long-acting dual GLP-1 and GIP receptor agonist, indicating potential beyond obesity. A Phase 1 multiple ascending dose study in 212 individuals (184 on brenipatide, 28 on placebo) showed overall mild side effects, with gastrointestinal (GI) treatment-emergent adverse effects (TEAEs) comparable between brenipatide and placebo groups (25% each). Brenipatide is now in Phase 3 trials for alcohol use disorder (RENEW-ALC-1) and major depressive disorder (RENEW-MDD-1), with topline data anticipated in early 2028. This marks Lilly's exploration of incretins in neuropsychiatric conditions.
- The Phase 1 multiple ascending dose study of brenipatide, involving 184 brenipatide-treated and 28 placebo-treated individuals, demonstrated overall mild side effects. A significant finding was that the frequency of gastrointestinal (GI) treatment-emergent adverse effects (TEAEs) was comparable between both groups, with 25% in brenipatide-treated participants and 25% in placebo-treated participants. This suggests a potentially improved GI tolerability profile compared to typical GIP/GLP-1 receptor agonists, which often face challenges with GI side effects.
- Brenipatide exhibited a notable half-life of nine to 12 days, which is particularly advantageous for neuroscience applications. This extended half-life allows for sustained drug levels between doses, minimizing peaks and troughs, and supports a convenient weekly subcutaneous injection regimen. This pharmacokinetic profile, combined with its dual GIP/GLP-1 action, is hypothesized to contribute to the observed lower GI side effects and enhance patient adherence.
- Brenipatide is currently in Phase 3 trials for major depressive disorder (RENEW-MDD-1) and moderate-to-severe alcohol use disorder (RENEW-ALC-1), with topline data anticipated in early 2028. The RENEW-ALC-1 trial's primary endpoint focuses on changes in drinking patterns, not complete abstinence. Additionally, brenipatide is being investigated in Phase 2 for opioid use disorder, tobacco use disorder, bipolar disorder, schizophrenia, asthma, irritable bowel syndrome, and chronic obstructive pulmonary disease (COPD), showcasing its broad therapeutic potential across multiple areas.
Incretins Chart a New Course in Neuropsychiatry
Lilly's ambitious move to advance brenipatide, a dual GLP-1 and GIP receptor agonist, into Phase 3 trials for alcohol use disorder (AUD) and major depressive disorder (MDD) represents a significant strategic pivot for the incretin class. Historically associated with metabolic diseases, these compounds are now being explored for their potential in neuropsychiatry, an area with substantial unmet needs and limited therapeutic innovation. The early Phase 1 data, particularly the observation of gastrointestinal (GI) treatment-emergent adverse effects (TEAEs) comparable to placebo, is a critical differentiator. Many drugs, even those designed to improve tolerability, frequently encounter GI issues, which can be a barrier to long-term adherence in chronic conditions. If this favorable tolerability profile holds in larger patient populations, brenipatide could offer a compelling advantage.
This initiative underscores a growing scientific interest in the gut-brain axis, a pathway increasingly recognized for its influence on mental health. Research indicates the ghrelin system, another gut-brain axis component, is involved in AUD pathophysiology, suggesting a broader role for gut hormones in neurological conditions. However, the path forward is not without its challenges. While promising, early-stage efficacy data for complex neuropsychiatric conditions often fails to translate into robust Phase 3 outcomes. The intricate neurobiological underpinnings of AUD and MDD, which involve factors like neuroinflammation, oxidative stress, and altered neurotransmitter systems, mean that a novel mechanism of action must demonstrate clear and sustained benefit. Furthermore, the long-term safety and tolerability in diverse patient populations, potentially on concomitant medications, will be crucial. Success for brenipatide would not only establish a new therapeutic frontier for incretins but also validate a novel approach to addressing some of the most debilitating and widespread mental health conditions globally.
Frequently Asked Questions
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
